Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.

Vico Therapeutics Secures €65.8M in Series B Funding Led by Seroba and Kurma Partners

Vico Therapeutics secures €65.8M in Series B funding led by Seroba and Kurma Partners to advance genetic medicines
June 24, 2024

In a significant boost to its innovative therapies for severe neurological diseases, Dutch based Vico Therapeutics has secured €65.8 million in Series B funding. This round was co-led by Seroba, a prominent European life sciences venture capital firm, and Kurma Partners, an influential player in healthcare and biotechnology investments.

Vico Therapeutics is at the forefront of developing genetic medicines for devastating neurodegenerative disorders. Its lead program, VO659, is currently undergoing a Phase 1/2a clinical study targeting spinocerebellar ataxia types 3 and 1, as well as Huntington’s disease. These conditions presently lack any disease-modifying treatments, underscoring the critical need for Vico’s innovative approach.

Seroba, headquartered in Dublin with additional offices in Paris and Milan, contributed €11.5 million to this funding round, joining forces with Kurma Partners' Growth Opportunities Fund. This collaboration will enable Vico to advance its lead clinical program and expand its portfolio of novel antisense oligonucleotides.

Catello Somma, Partner at Seroba, expressed the firm’s enthusiasm: “We are extremely proud to support Vico in this financing round and join the existing investors. The growth capital will help the Company to bolster its clinical programs to deliver life-changing outcomes for patients with polyQ diseases, such as SCA and Huntington's. We are excited to partner with Vico and its remarkable team as the Company advances its programs.”

Similarly, Daniel Parera and Jean-Francois Rivassou, Partners at Kurma, highlighted the strategic value of their continued investment: “Vico is another very nice example of a company where Kurma Partners acted as a co-founding investor that has progressed into clinical development. Our Growth Opportunities Fund is able to add further support to Vico and its experienced management team in the continuation of Vico’s path together with existing investors.”

The consortium of investors supporting this round includes Ackermans & van Haaren (AvH), Droia Ventures, EQT Life Sciences, Eurazeo, Kurma Biofund, Polaris Partners, and Pureos Bioventures. This robust financial backing is set to propel Vico Therapeutics forward, fostering advancements in genetic medicine and offering hope to patients suffering from severe neurological diseases.

Last related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram